- Home
- ACRV vs MCRB Comparison
ACRV vs MCRB Comparison
Compare ACRV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- MCRB
- Stock Information
- Founded
- ACRV 2018
- MCRB 2010
- Country
- ACRV United States
- MCRB United States
- Employees
- ACRV N/A
- MCRB N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- MCRB Health Care
- Exchange
- ACRV Nasdaq
- MCRB Nasdaq
- Market Cap
- ACRV 59.9M
- MCRB 81.2M
- IPO Year
- ACRV 2022
- MCRB 2015
- Fundamental
- Price
- ACRV $1.18
- MCRB $6.96
- Analyst Decision
- ACRV Strong Buy
- MCRB Hold
- Analyst Count
- ACRV 5
- MCRB 5
- Target Price
- ACRV $19.75
- MCRB $73.67
- AVG Volume (30 Days)
- ACRV 1.3M
- MCRB 141.1K
- Earning Date
- ACRV 05-13-2025
- MCRB 05-07-2025
- Dividend Yield
- ACRV N/A
- MCRB N/A
- EPS Growth
- ACRV N/A
- MCRB N/A
- EPS
- ACRV N/A
- MCRB 0.03
- Revenue
- ACRV N/A
- MCRB N/A
- Revenue This Year
- ACRV N/A
- MCRB N/A
- Revenue Next Year
- ACRV N/A
- MCRB N/A
- P/E Ratio
- ACRV N/A
- MCRB $208.01
- Revenue Growth
- ACRV N/A
- MCRB N/A
- 52 Week Low
- ACRV $1.30
- MCRB $7.18
- 52 Week High
- ACRV $10.29
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- ACRV 29.23
- MCRB 32.32
- Support Level
- ACRV $1.32
- MCRB $8.92
- Resistance Level
- ACRV $1.50
- MCRB $9.97
- Average True Range (ATR)
- ACRV 0.19
- MCRB 1.10
- MACD
- ACRV 0.06
- MCRB -0.01
- Stochastic Oscillator
- ACRV 2.08
- MCRB 1.51
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.